[Inhibition of growth hormone in insulin-dependent diabetics after oral administration of pirenzepine. Fluorophotometric study of the vitreous body]. 1994

J M Benitez del Castillo, and J L Ruibal, and F Reverte, and G Seara, and P C Fernandez, and S Duran, and E Casado, and J Garcia Sanchez
Département d'Ophtalmologie, Hôpital Universitaire de San-Carlos, Madrid, Espagne.

The purpose of our study was to quantify the blood-retinal barrier permeability in five patients with insulin-dependent diabetic (mean age 14.96 +/- 2.45 years) without retinopathy, after six month with oral pirenzepine, a growth hormone inhibitor. Blood-retinal barrier permeability was determined by vitreous fluorophotometry before and after treatment with a nocturnal oral dose of pirenzepine (0.6 mg/kg the first month and 1 mg/kg the following five months). We found a significant diminution (p < 0.05) in growth hormone levels (10.48 +/- 4.94 ng/ml before treatment and 4.35 +/- 2.53 ng/ml after treatment), nevertheless, no changes in the blood-retinal barrier permeability values were observed (4.84 +/- 2.08 x 10(-6) min-1 before treatment and 4.53 +/- 2.54 x 10(-6) min-1 after treatment). We found no modifications in the levels of somatomedin C or HbA1c either. It can be concluded that oral pirenzepine used at this dose for six months, in spite of a significant decrease in growth hormone secretion, does not decrease the permeability of the blood-retinal barrier.

UI MeSH Term Description Entries
D008297 Male Males
D010890 Pirenzepine An antimuscarinic agent that inhibits gastric secretion at lower doses than are required to affect gastrointestinal motility, salivary, central nervous system, cardiovascular, ocular, and urinary function. It promotes the healing of duodenal ulcers and due to its cytoprotective action is beneficial in the prevention of duodenal ulcer recurrence. It also potentiates the effect of other antiulcer agents such as CIMETIDINE and RANITIDINE. It is generally well tolerated by patients. Gastrotsepin,Gastrozepin,L-S 519,LS-519,Piren-Basan,Pirenzepin,Pirenzepin Von Ct,Pirenzepin-Ratiopharm,Pirenzepine Dihydrochloride,Pyrenzepine,Ulcoprotect,Ulgescum,Dihydrochloride, Pirenzepine,LS 519,LS519,Piren Basan,Pirenzepin Ratiopharm,Von Ct, Pirenzepin
D001813 Blood-Retinal Barrier A specialized transport barrier, in the EYE, formed by the retinal pigment EPITHELIUM, and the ENDOTHELIUM of the BLOOD VESSELS of the RETINA. TIGHT JUNCTIONS joining adjacent cells keep the barrier between cells continuous. Retinal-Blood Barrier,Barrier, Blood-Retinal,Barrier, Retinal-Blood,Barriers, Blood-Retinal,Barriers, Retinal-Blood,Blood Retinal Barrier,Blood-Retinal Barriers,Retinal Blood Barrier,Retinal-Blood Barriers
D003922 Diabetes Mellitus, Type 1 A subtype of DIABETES MELLITUS that is characterized by INSULIN deficiency. It is manifested by the sudden onset of severe HYPERGLYCEMIA, rapid progression to DIABETIC KETOACIDOSIS, and DEATH unless treated with insulin. The disease may occur at any age, but is most common in childhood or adolescence. Diabetes Mellitus, Brittle,Diabetes Mellitus, Insulin-Dependent,Diabetes Mellitus, Juvenile-Onset,Diabetes Mellitus, Ketosis-Prone,Diabetes Mellitus, Sudden-Onset,Diabetes, Autoimmune,IDDM,Autoimmune Diabetes,Diabetes Mellitus, Insulin-Dependent, 1,Diabetes Mellitus, Type I,Insulin-Dependent Diabetes Mellitus 1,Juvenile-Onset Diabetes,Type 1 Diabetes,Type 1 Diabetes Mellitus,Brittle Diabetes Mellitus,Diabetes Mellitus, Insulin Dependent,Diabetes Mellitus, Juvenile Onset,Diabetes Mellitus, Ketosis Prone,Diabetes Mellitus, Sudden Onset,Diabetes, Juvenile-Onset,Diabetes, Type 1,Insulin Dependent Diabetes Mellitus 1,Insulin-Dependent Diabetes Mellitus,Juvenile Onset Diabetes,Juvenile-Onset Diabetes Mellitus,Ketosis-Prone Diabetes Mellitus,Sudden-Onset Diabetes Mellitus
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D013006 Growth Hormone A polypeptide that is secreted by the adenohypophysis (PITUITARY GLAND, ANTERIOR). Growth hormone, also known as somatotropin, stimulates mitosis, cell differentiation and cell growth. Species-specific growth hormones have been synthesized. Growth Hormone, Recombinant,Pituitary Growth Hormone,Recombinant Growth Hormone,Somatotropin,Somatotropin, Recombinant,Growth Hormone, Pituitary,Growth Hormones Pituitary, Recombinant,Pituitary Growth Hormones, Recombinant,Recombinant Growth Hormones,Recombinant Pituitary Growth Hormones,Recombinant Somatotropins,Somatotropins, Recombinant,Growth Hormones, Recombinant,Recombinant Somatotropin
D015590 Fluorophotometry Measurement of light given off by fluorescein in order to assess the integrity of various ocular barriers. The method is used to investigate the blood-aqueous barrier, blood-retinal barrier, aqueous flow measurements, corneal endothelial permeability, and tear flow dynamics. Ocular Fluorophotometry,Vitreous Fluorophotometry,Fluorophotometry, Ocular,Fluorophotometry, Vitreous

Related Publications

J M Benitez del Castillo, and J L Ruibal, and F Reverte, and G Seara, and P C Fernandez, and S Duran, and E Casado, and J Garcia Sanchez
June 1984, Investigative ophthalmology & visual science,
J M Benitez del Castillo, and J L Ruibal, and F Reverte, and G Seara, and P C Fernandez, and S Duran, and E Casado, and J Garcia Sanchez
September 1987, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme,
J M Benitez del Castillo, and J L Ruibal, and F Reverte, and G Seara, and P C Fernandez, and S Duran, and E Casado, and J Garcia Sanchez
September 1992, Metabolism: clinical and experimental,
J M Benitez del Castillo, and J L Ruibal, and F Reverte, and G Seara, and P C Fernandez, and S Duran, and E Casado, and J Garcia Sanchez
November 1986, Clinical endocrinology,
J M Benitez del Castillo, and J L Ruibal, and F Reverte, and G Seara, and P C Fernandez, and S Duran, and E Casado, and J Garcia Sanchez
February 1989, The Journal of clinical endocrinology and metabolism,
J M Benitez del Castillo, and J L Ruibal, and F Reverte, and G Seara, and P C Fernandez, and S Duran, and E Casado, and J Garcia Sanchez
April 1992, Anales espanoles de pediatria,
J M Benitez del Castillo, and J L Ruibal, and F Reverte, and G Seara, and P C Fernandez, and S Duran, and E Casado, and J Garcia Sanchez
January 1998, Klinika oczna,
J M Benitez del Castillo, and J L Ruibal, and F Reverte, and G Seara, and P C Fernandez, and S Duran, and E Casado, and J Garcia Sanchez
November 1986, Archives of ophthalmology (Chicago, Ill. : 1960),
J M Benitez del Castillo, and J L Ruibal, and F Reverte, and G Seara, and P C Fernandez, and S Duran, and E Casado, and J Garcia Sanchez
November 1976, Journal of toxicology and environmental health,
J M Benitez del Castillo, and J L Ruibal, and F Reverte, and G Seara, and P C Fernandez, and S Duran, and E Casado, and J Garcia Sanchez
October 1984, The Journal of clinical endocrinology and metabolism,
Copied contents to your clipboard!